Humacyte Gross Profit

The latest gross profit for HUMA is $-2.4M as of June 2026. That compares with $3.7M in the prior-year period — down 164.0% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Humacyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, HUMA's gross profit moved from $3.7M to $-2.4M — a 164.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Humacyte's operating scale or balance-sheet position.

Against Healthcare companies, HUMA currently prints $-2.4M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Humacyte's growth, margins, and balance sheet.

A gross profit figure of $-2.4M for HUMA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting HUMA's gross profit ($-2.4M), review year-over-year change from $3.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.